## Platinum-Sensitive Recurrent Ovarian Cancer: Re-treatment Strategy **Key Point:** Platinum-sensitive recurrent ovarian cancer (recurrence >6 months after last platinum) should be re-challenged with platinum-based combination chemotherapy, preferably paclitaxel + carboplatin. ### Definition & Rationale **Platinum-Sensitive Disease:** - Recurrence ≥6 months after completion of platinum-based chemotherapy - Associated with retention of platinum sensitivity and good prognosis for re-treatment - Platinum re-challenge is the standard of care ### Why Paclitaxel + Carboplatin for Platinum-Sensitive Recurrence? 1. **Evidence** - ICON 4 and AGO-OVAR 2.5 trials demonstrated superior outcomes with platinum + paclitaxel vs. platinum alone - Response rates 60–70% in platinum-sensitive patients - Median PFS 12–14 months with combination therapy 2. **Mechanism of Efficacy** - Tumor cells retain platinum sensitivity after initial treatment interval - Combination chemotherapy (platinum + taxane) is more effective than single-agent therapy - Synergistic cytotoxicity ### Single-Agent Alternatives (When Combination Not Feasible) | Drug | Use Case | Notes | |------|----------|-------| | Pegylated liposomal doxorubicin (PLD) | Platinum-sensitive, poor performance status | Lower response rate; less preferred | | Topotecan | Platinum-sensitive, prior taxane intolerance | Topoisomerase I inhibitor; second choice | | Gemcitabine | Limited data; rarely used as monotherapy | Not standard | **High-Yield:** Platinum-sensitive recurrence = re-challenge with platinum + taxane. Single-agent therapy is reserved for patients unable to tolerate combination chemotherapy. **Warning:** Do NOT confuse platinum-sensitive (≥6 months) with platinum-resistant (<6 months). Platinum-resistant disease has poor response to re-challenge and requires alternative strategies (bevacizumab, PARP inhibitors, or non-platinum chemotherapy). **Clinical Pearl:** The interval from last platinum therapy is the strongest predictor of re-treatment response. Longer intervals correlate with higher response rates and better outcomes.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.